Detalhe da pesquisa
1.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
N Engl J Med
; 382(14): 1331-1342, 2020 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242358
2.
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Blood
; 138(1): 11-22, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827116
3.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 23(1): 91-103, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895487
4.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Lancet
; 398(10299): 491-502, 2021 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097852
5.
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Br J Haematol
; 195(3): 388-398, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590303
6.
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Br J Haematol
; 194(4): 690-700, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34296427
7.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol
; 20(1): 31-42, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30518502
8.
Candida albicans Zn Cluster Transcription Factors Tac1 and Znc1 Are Activated by Farnesol To Upregulate a Transcriptional Program Including the Multidrug Efflux Pump CDR1.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30104273
9.
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
Blood
; 138(12): 1081-1085, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34041526
10.
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Mol Ther
; 25(1): 285-295, 2017 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28129122
11.
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 135(23): 2106-2109, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32181801
12.
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Nat Med
; 28(9): 1872-1882, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36038629
13.
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Am J Cancer Res
; 11(6): 3285-3293, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34249462
14.
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
Cancer Discov
; 11(3): 599-613, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33334730
15.
Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33067318
16.
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
Blood Adv
; 4(19): 4898-4911, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33035333
17.
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.
Blood Adv
; 6(20): 5634-5640, 2022 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858291
18.
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
Bone Marrow Transplant
; 55(6): 1184-1187, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471571
19.
Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.
PLoS One
; 10(3): e0122149, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25807104
20.
Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.
Cancer Cell
; 26(2): 177-89, 2014 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25043603